A：The key highlights of Johnson & Johnson's second quarter 2026 financial performance include operational sales growth of 5.6% and meeting the 2026 target of more than $100 billion in annual revenue for the first time in the company's 140-year history. They also reported that sales in the quarter were more than $25 billion. The company is on track to deliver a cross oncology, immunology, neuroscience, cardiovascular surgery, and is built on a unique combination of scientific expertise, scale, and disciplined execution. Additionally, they have the strongest portfolio and pipeline in their 140-year history with 28 products and platforms that each deliver more than a billion dollars in annual sales.

A：Johnson & Johnson anticipated a year of accelerated growth and impact for the year 2026, as stated by their CEO. The company is delivering a cross oncology, immunology, neuroscience, cardiovascular surgery, and they raised guidance, which signifies a strong overall performance.

A：The operational sales growth was driven by products like I in, which had a significant launch momentum, and Dar Selects, the foundational treatment for multiple myeloma. Additionally, in oncology, there was a commitment to improving patient outcomes, with plans to be the number one oncology company by 2030, projecting sales to exceed $50 billion.

A：The reported operational sales growth for the second quarter is 5.6%, and the revenue for the quarter is more than $25 billion.

A：Strategic acquisitions mentioned for advancing Johnson & Johnson's oncology portfolio include plans to acquire Firefly Bio, which adds another antibody platform to strengthen the company's leadership in next-generation oncology innovation, with the expectation to close the transaction during the third quarter.

A：In the Immunology sector, Johnson & Johnson has built one of the deepest and most differentiated portfolios in the industry, with Strefa A and Icoty in psoriasis driving exceptional overall sales growth of 71% in the quarter.

A：In the Neuroscience sector, Johnson & Johnson is developing treatments to transform care for complex brain and nervous system disorders. Spravato and Kalita both performed strongly in the quarter with new patient starts up 122% versus the prior year, and FDA approval for the prevention of relapse in schizophrenia was received, continuing momentum.

A：In the Medtech sector, Johnson & Johnson delivered Q2 operational sales growth of 3.6% in cardiovascular. They are global leaders in electrophysiology, circulatory restoration, and heart recovery. They received FDA authorization for their dual energy thermocool Smart Touches SF platform and launched Wave C 2 A to treat more complex coronary disease.

A：Johnson & Johnson is aiming to make vision possible for more than 40 million people each year. They announced the expanded U.S. availability of Technis PC, which is an extended depth of focus intraocular lens, and this, along with their Acube portfolio, delivered strong quarterly growth across all regions. As part of their $55 billion U.S. commitment, they announced an investment of more than $1 billion to scale their U.S. manufacturing, packaging, and distribution capabilities.

A：Financial results for the quarter include net earnings of $5.5 billion and diluted earnings per share of $2.27. The adjusted net earnings for the quarter were $7.1 billion with adjusted diluted earnings per share of $2.90. Key business areas like Innovative Medicine, which includes oncology, immunology, and neuroscience, contributed to the financial results with worldwide sales of $16.4 billion, reflecting the depth of expertise and innovation in areas of high unmet need.

A：The growth rate of Riber VA plus last clues in prostate cancer was 61.6%, driven by continued launch uptake in all regions and share gains in the first and second lines with rapid uptake of Riber ramp.

A：Overall cardiovascular grew 3.1%, with growth driven by procedure growth, commercial execution, and new product performance, partially offset by competitive PFA pressures and a negative impact from China inventory.

A：Solara declined 55.7% due to share loss attributable to biosimilar competition, increasing adoption of novel classes, and unfavorable patient mix.

A：Surgical vision grew 4.7%, driven by new product innovations, robust demand for premium IOLs, and strong commercial execution, partially offset by competitive pressures and divestiture.

A：Cost of goods sold leveraged by 30 basis points, selling, marketing, and administrative expenses deleveraged by 5 basis points, research and development leveraged by 40 basis points, interest income and expense was a net expense of $62 million compared to $48 million in the second quarter of 2025, and other income and expense was a net expense of $331 million compared to $107 million in the second quarter of 2025.

A：The effective rate in the second quarter of 2026 was 18%, compared to 14.7% in the second quarter of 2025.

A：The adjusted income before tax net earnings and earnings per share were not provided in the provided text.

A：The updated expectation for operational sales growth for the full year is in the range of 6% to 8% with a midpoint of $100.6 billion, with a benefit of approximately 100 basis points due to a 53rd week in 2026.

A：The updated outlook for adjusted operational earnings per share is $11.50 to $11.65, representing year-on-year adjusted operational EPS growth of 7.3%, and the reported earnings per share is projected to be $11.60 to $11.75 or $11.68 at the midpoint, representing an 8.2% increase over the prior year.

A：The current outlook does not include the impact of any pending acquisitions such as Firefly Bio.

A：The anticipated regulatory approval is for amavi as the first treatment for warm autoimmune hemolytic anemia. Important data readouts include Tech Valley in combination with talvez for patients with relapse refractory multiple myeloma, castrata m for advanced prostate cancer, and JJ 6143 for metastatic castration-resistant prostate cancer. Data readouts are also expected for in lexo in high risk non muscle invasive bladder cancer, and I type in A of arthritis and cap in bipolar mania.

A：The cardiovascular segment is expected to see momentum from launches such as the dual energy thermocool smart touch SF platform, Shockwave C 2 Aero and aero fly IVL catheters, and the continued adoption of cardio sound sonata cardio mapping. Additionally, the EMEA launch of ethecon script and envision is anticipated, as well as the expansion of availability of technos pure sea intertrabecular lens for cataract and presbyopia, and the adoption of Acuvue Oasis Max lenses.

A：The company continues to evaluate all options that create shareholder value and set the Depew cynthesis business up for long-term success. They are on track for a mid-2027 separation and look forward to sharing updates later in the year.

A：The $400 million increase in operational sales guidance is expected to be a fair characterization, with a shift between pharma and med tech components. The company had previously projected better revenue growth for the second half of the year, and while they expect Medtech to grow better in the second half than the first half, they have tempered expectations around the abiomed business. Growth in pharmaceuticals is attributed to products like ikka, ti, in lexo, and trem FIA, which have been performing well.

A：The prescribed accounts for ICA Ti are progressing well. Over 18,000 prescriptions have been written for a total of 11,000 patients, with 6,000 unique prescribers. About 50% of these prescribers are advanced practice providers, 40% are dermatologists, and the rest are primary care physicians. The company has also observed a number of repeat prescriptions and over 50% of commercial coverage within 90 days, which is ahead of projections.

A：ICA Ti is positioned as the first choice systemic treatment for patients who have cycled on topicals and need advanced therapy. It is seen as the first choice biologic, particularly for patients with potential for or who have psoriatic arthritis involvement. The company believes that ICA Ti and trem fire fit well in the treatment spectrum and are addressing distinct and unique positions in the market.

A：The company's outlook on procedure growth in the US for Q2 is stable with no evidence of a broad slowdown in demand. For the rest of the year, the expectation is for Medtech growth to be faster than the first half, which was 4.2%. They anticipate Medtech to grow faster in 2026, including the extra week.

A：The Q2 growth in the CV business was impacted by a muted growth in EP and heart recovery, partially offset by continued double-digit growth in Shockwave in EP. A significant inventory dynamic in China impacted growth by about 400 basis points. Impella usage slowed due to a recent neutral clinical trial in the UK, but the company is actively engaging with physicians and teams to reinforce appropriate patient selection and leveraging their clinical evidence base. Despite this, 3 out of 4 businesses performed well, and the company is confident in addressing the fourth. There are no changes to their long-term growth thesis for the CV business or the medtech segment.

A：The company views procedure volumes as generally in line with market trends and not showing any broad-based slowdown. Demand remains consistent with expectations based on market fundamentals, including themes such as aging populations and increasing disease prevalence. They are monitoring the pressure on procedure volumes in elective areas of care as highlighted by large hospital operators, but this is not reflected in their portfolio results today. Furthermore, they do not expect the removal of Affordable Care Act subsidies to have a meaningful impact on procedure volumes or their medtech performance, as they have not observed any meaningful impact across their portfolio related to the ACA.

A：Tech Valley had a great quarter with sales growth of 56% versus the prior year, driven by significant launch uptake and share gains across earlier lines of therapy based on recent approvals in the US for Tech Valley plus Darzalex, as well as continued expansion in the community setting. The approval of the combination regimen is the first and only steroid-free, readily available, immediate immunotherapy option with best-in-class efficacy and potential for cure in the second line setting. At 3 years, 83% of patients remain alive and progression-free, which is resonating with physicians and driving strong early US demand following the rapid approval for Tech Valley plus Darzalex.

A：The company is awaiting approval of Otava, which was submitted late last year, and is actively working on second clinical trials for inguinal hernia. They are committed to the launch of Otava and the launch of Monarch for Urology, which will be a first-of-kind opportunity. The company will provide more information about these launches next week and update on the Forte trial results. They are confident in the performance of the robots Otava and Monarch, which they believe will be meaningful contributors to growth by the end of the decade.

A：The launch of Ino is going well, with one in three eligible patients now starting on an Ino regimen in the US. This is an uptick from one in four patients last quarter. Ino is outperforming competitive launches and leading in new patient share and new patient insertions, with a 75% growth in quarter-over-quarter growth. Ino is included in the NCCN guidelines with a Category 2A designation and has seen an update to include the papillary population, representing about 80% of BCG-unresponsive patients. The company believes it's on a very good track with Ino's performance. They also mentioned the upcoming Sunrise 5 data and expectations for what they hope to see from that data, particularly regarding patient numbers and prescriber numbers.

A：The idefi nib is a targeted therapy positioned for intermediate risk non-muscle invasive bladder cancer, offering sustained delivery of medicine for three months, which is a novel approach in this area of treatment.

A：The study is event-driven and fully recruited, meaning it cannot provide precise timing for results, which are expected towards the end of the year or beginning of the next. The study's endpoints or 'events' must occur before full results can be read out.

A：The Novax and opportunity is considered significant because it has the potential for a better bleeding profile than current anticoagulants, addressing the concerns of 40% of atrial fibrillation patients who are not receiving oral anticoagulants due to bleeding risks. It could be a game changer for these patients and represent a significant market opportunity.

A：The new growth expectation for the Abiomed business is still a mid-teens growth, despite the current slowdown attributed to the data presented at the ACC, which impacted the company's performance.

A：The slowdown in the Abiomed business is primarily due to physician caution following new data from the UK. The company is addressing this through active engagement with physicians and their teams to reinforce appropriate patient selection and emphasizing the importance of clinical evidence base.

A：The impact of the new study on the Impella product line is behavioral, driven by physician caution, but there is no change in the underlying need, access, or reimbursement. With more than 400,000 Impella-supported patients and over 2,600 peer-reviewed publications, the company continues to see Impella as a valuable tool in the hands of appropriately selected patients.

A：The company anticipates that its performance will take some time to recover, but it expects the back half of the year to be stronger than the first half and to see gradual improvements leading to double-digit growth over the coming quarters.

A：Tim believes that the current situation does not affect the company's growth trajectory and that the second half of the year is expected to be stronger, with continued double-digit growth into 2027.

A：Tremfya in GI disease is considered to have an edge due to its ability to hold market share against competitors like skyrizi. The major driver of growth is performance in ulcerative colitis and Crohn's disease, with market leadership in new patient starts and induction share.

A：The sub Q induction method for Tremfya is providing great traction for patients and healthcare providers by offering a simple and convenient at-home auto-injector, which allows patients to start treatment without the need for two different priorities.